BridgeMD
New treatment option for Acute Coronary Syndrome
Official title OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
ClinicalTrials.gov ID: NCT06216821
What this study is testing
What is standard DAPT?
standard DAPT is an investigational medicine, being studied as a potential treatment for acute coronary syndrome.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adult patients with ages of 18-80 years;
- Patients with clinically diagnosed ACS who have undergone at least one DES implantation;
- Individuals capable of completing the OPT-CAD scoring calculation;
- Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy;
- Written informed consent provided.
You likely can't join if
- Left main coronary artery lesion PCI;
- Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor;
- Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria;
- Anticipated need for revascularization or surgical intervention within 12 months;
- Severe ischemia or hemorrhage events during the current hospitalization;
- Life expectancy of other serious diseases is less than 1 year;
See the full eligibility criteria
- Adult patients with ages of 18-80 years;
- Patients with clinically diagnosed ACS who have undergone at least one DES implantation;
- Individuals capable of completing the OPT-CAD scoring calculation;
- Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy;
- Written informed consent provided.
- Left main coronary artery lesion PCI;
- Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor;
- Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria;
- Anticipated need for revascularization or surgical intervention within 12 months;
- Severe ischemia or hemorrhage events during the current hospitalization;
- Life expectancy of other serious diseases is less than 1 year;
- Pregnant or women of childbearing age who intend to conceive within 1 year;
- Participation in other clinical trials while still under observation;
- Researchers considering ineligibility for enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.